



Diagnosing and Treating Irritable Bowel Syndrome (IBS-D) for Primary Care Clinicians

9/25/2019

This activity was created to address the professional practice gaps listed below:

- Describing the pathogenesis of IBS.
- Identifying early symptoms of IBS which is leading to misdiagnosis and mistreatment of patients.
- Recognizing the latest research findings that identify the underlying physiologic and psychological determinants for treating and managing IBS.
- Utilizing the new FDA approved treatment options for IBS.

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Strongly Disagree			Strongly Agree
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [11-3.64]	(1) 9.09%	(0)	(1) 9.09%	(9) 81.82%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [10-3.40]	(1) 10.00%	(0)	(3) 30.00%	(6) 60.00%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [9-3.22]	(2) 22.22%	(0)	(1) 11.11%	(6) 66.67%

2. Please elaborate on your previous answers. (4)

I have more knowledge now about IBS compared to before especially speaker said that if a patient doesn't have abd'l pain aside from the other signs and symptoms, then it's not IBS.

EXCELLENT TALK.

I do not work in primary care, but found the topic of interest.

3. Please evaluate the effectiveness of the speaker(s) that presented at your session in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Fouad Moawad, MD [10-3.90]	(0)	(0)	(1) 10.00%	(9) 90.00%
Brooks Cash, MD [2-3.50]	(0)	(0)	(1) 50.00%	(1) 50.00%

Anthony Lembo, MD [3-4.00]	(0)	(0)	(0)	(3)100%
Lucinda Harris, MD [2-4.00]	(0)	(0)	(0)	(2)100%

4. Please elaborate on your previous answers. (3)

MD was an expert in that field, he was able to answer questions thrown out from the audience.

Experienced and knowledgeable on the subject
 very clear and answered all questions.

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (6)

N/a
 I know now that rifaximin is also used to treat IBS; so if I have a patient who was on this med from home, then I would probably entertain that he has history of IBS
 none
 Managing diet, medication, lifestyle change, and stress
 Have a greater understanding of the medications used to treat IBS that my patients might be on.
 dietary recommendations

6. How certain are you that you will implement this change? (10)

Certain ⁽⁷⁻ 70.00%)
 Very Certain ⁽¹⁻ 10.00%)
 N/A ⁽²⁻ 20.00%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (2)
 pulmonary disease

8. Were the patient recommendations based on acceptable practices in medicine? (9)

Yes ⁽⁹⁻ 100.00%)

10. Do you think the presentation was without commercial bias? (9)

Yes ⁽⁷⁻ 77.78%)
 No ⁽²⁻ 22.22%)

12. Please provide any additional comments you may have about this educational activity. (2)

brief and concise

It was very interesting and I was very glad I was able to attend.

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.



Treating Irritable Bowel Syndrome and Chronic Idiopathic Constipation For Primary Care Clinicians

10/27/2020

This activity was created to address the professional practice gaps listed below:

- Describing the pathogenesis of IBS.
- Identifying early symptoms of IBS which is leading to misdiagnosis and mistreatment of patients.
- Recognizing the latest research findings that identify the underlying physiologic and psychological determinants for treating and managing IBS.
- Utilizing the new FDA approved treatment options for IBS.

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Disagree		Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [3-4.00]	(0)	(0)	(0)	(3)100%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [3-3.67]	(0)	(0)	(1) 33.33%	(2) 66.67%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [3-3.00]	(0)	(1) 33.33%	(1) 33.33%	(1) 33.33%

2. Please elaborate on your previous answers. (2)

The information was very practical and presented in a straight forward manner so I can apply it to my practice in a meaningful way.

do not work in GI or PC, but still will help me assist pts in getting to a provider to treat issues

3. Please evaluate the effectiveness of the following speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Fouad J. Moawad, MD [3-4.00]	(0)	(0)	(0)	(3)100%

4. Please elaborate on your previous answers. (2)

Very well constructed slides, very well organized, and very well presented. I could tell he is well grounded in both knowledge and application of the material presented.

the general overview and outline flowed very well. engaging speaker even on virtual format. also gave his treatment options and obstacles for different patient situations which is VERY helpful so that we can apply knowledge to real life circumstances.

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (2)

I work in primary care so this gives me some additional options to try before sending my patients to GI. This is especially helpful since the majority of my patients do not have insurance.

exposed to new medication offerings. learned more about FODMAP" diet.

6. How certain are you that you will implement this change?

(2)

Very Certain ⁽¹⁻
50.00%)

Certain ⁽¹⁻
50.00%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (1)

opioid induced constipation treatment options in post op patients

8. Were the patient recommendations based on acceptable practices in medicine?

(2)

Yes ⁽²⁻
100.00%)

10. Do you think the presentation was without commercial bias?

(2)

Yes ⁽²⁻
100.00%)

12. Please provide any additional comments you may have about this educational activity. (1)

EXCELLENT TALK!!!

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.